Given the pivotal roles of Tim-3 and PD-1 in suppressing antitumor immunity, concurrent blockade of both pathways represents a promising strategy to enhance response rates and overcome resistance in cancer patients who exhibit limited benefit from anti-PD-1/PD-L1 monotherapy (20, 21). Here, HAVCR2 is linked to cancer.